Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5829 (Alobresib) as a Single Agent and In Combination With Enzalutamide in Participants With Metastatic Castrate-Resistant Prostate Cancer

Clinical trial NCT02607228 · TERMINATED

Trial details

NCT number

NCT02607228

Sponsor

Gilead Sciences

Status

TERMINATED

Phase

Phase 1, Phase 2

Study type

INTERVENTIONAL

Start date

2015-12-08

Primary completion

2017-10-25

Enrollment

31

View on ClinicalTrials.gov